Telik, Inc.

Telik, Inc. (Nasdaq: TELK) of Palo Alto, CA is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. Our most advanced development candidate is TELCYTA™ (TLK286), a novel cancer cell-activated chemotherapeutic currently in four Phase 3 registration trials in advanced ovarian cancer and non-small cell lung cancer. A second development candidate, TELINTRA™ (TLK199), is in a Phase 2 clinical trial in myelodysplastic syndrome and may also have utility in the treatment of additional blood disorders characterized by low levels of blood cells.

We developed our product candidates through the use of our proprietary TRAP™ technology, which enables the rapid and efficient discovery of small molecule drug candidates. In addition to our internal drug development programs, we partner with select academic institutions and pharmaceutical and biotechnology companies to apply TRAP™ to new drug development programs for a range of diseases.

We intend to commercialize our cancer products in North America, and to partner with multinational pharmaceutical companies to assist in the commercialization of our cancer products in other territories.